Harrow entered into an agreement to acquire Melt Pharmaceuticals and plans to submit a new drug application for MELT-300, ...

Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of ophthalmic disease management solutions, announced on Friday that it ...

Harrow plans to submit a New Drug Application (“NDA”) to the FDA in 2027, with a potential U.S. commercial launch in 2028.

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation ...

Harrow (NASDAQ:HROW) to acquire Melt Pharmaceuticals, a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, ...

Netherlands: Midazolam sedation can noticeably restrict the natural adaptability of breathing, while s-ketamine largely ...

A 2024 Associated Press investigation into in-custody deaths examined 94 cases nationally involving forced sedation between 2012 and 2021 ... knelt down and injected him in the buttocks with midazolam ...

Purpose: To compare the analgosedative efficacy and safety of the combination of midazolam and fentanyl with those of midazolam monotherapy in mechanically ventilated neonates. Materials and methods: ...

The new head of the Fort Monroe Foundation is looking to turn the historic fort into a park of the future. Aazia Mrozinski, a leader experienced in innovation and community-building, took the reins as ...